title: Menstrual disorders in girls with systemic lupus erythematosus treated with cyclophosphamide.
abstract: To study the ovarian toxicity associated with cyclophosphamide in girls with systemic lupus erythematosus (SLE), we retrospectively reviewed the charts of 30 SLE girls aged 16 yr or younger at diagnosis, followed at three university hospitals. Gynaecological history was extracted from the charts or obtained prospectively. Ten had not received cyclophosphamide therapy, six were treated with daily oral cyclophosphamide, 10 with intravenous pulses and four with daily oral and intravenous pulses. Median oral cyclophosphamide dose was 38 g (inter-quartile range 75) and median intravenous dose 12.95 g (inter-quartile range 6.2). Six girls had oligomenorrhoea (20%) and one amenorrhoea (3%). Two treated with oral cyclophosphamide had oligomenorrhoea (33%) and one amenorrhoea (17%), two treated with both oral and intravenous pulses had oligomenorrhoea (50%), and none of those treated with intravenous pulses alone had menstrual disturbances (50% oral vs 0% intravenous pulses; P = 0.016). Girls who had menstrual disturbances had received higher doses of cyclophosphamide than those who did not (medians: 63 vs 15 g; P < 0.05). In summary, menstrual disturbances in SLE girls treated with cyclophosphamide are related to the total dose and perhaps to the administration method.
authors.affiliation: Department of Rheumatology and Paediatrics, Hospital Doce de Octubre, Spain.
authors.forename: M R
authors.initials: MR
authors.lastname: Gonzalez-Crespo
authors.forename: J J
authors.initials: JJ
authors.lastname: Gomez-Reino
authors.forename: R
authors.initials: R
authors.lastname: Merino
authors.forename: E
authors.initials: E
authors.lastname: Ciruelo
authors.forename: F J
authors.initials: FJ
authors.lastname: Gomez-Reino
authors.forename: R
authors.initials: R
authors.lastname: Muley
authors.forename: J
authors.initials: J
authors.lastname: Garcia-Consuegra
authors.forename: V
authors.initials: V
authors.lastname: Pinillos
authors.forename: V
authors.initials: V
authors.lastname: Rodriguez-Valverde
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000568:Amenorrhea / Q000139:chemically induced*; D002648:Child; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D008499:Medical Records; D009839:Oligomenorrhea / Q000139:chemically induced*; D012189:Retrospective Studies
chemical_list: D003520:Cyclophosphamide